HDAC6 inhibition enhances the anti-tumor effect of eribulin through tubulin acetylation in triple-negative breast cancer cells

Improved prognosis for triple-negative breast cancer (TNBC) has plateaued and the development of novel therapeutic strategies is required. This study aimed to explore anti-tumor effect combined eribulin HDAC inhibitor (vorinostat: VOR, pan-HDAC ricolinostat: RICO, selective HDAC6 inhibitor) treatment TNBC. The in combination with an was tested three TNBC cell lines (MDA-MB-231, Hs578T, MDA-MB-157) their eribulin-resistant derivatives. expression acetylated ?-tubulin analyzed by Western blotting cells immunohistochemical analyses clinical specimens obtained from patients who were treated eribulin. simultaneous administration low concentrations (0.2 ?M) VOR or RICO enhanced MDA-MB-231 Hs578T but not MDA-MB-157 cells. Meanwhile, pretreatment 5 ?M sensitivity all lines. Low concentration increased In contrast, whereas cells, did not. Eribulin These phenomena also observed Immunohistochemical revealed that after inhibition enhances through acetylation ?-tubulin. therapy could represent a strategy